Correlation Between Durect and Cidara Therapeutics

Can any of the company-specific risk be diversified away by investing in both Durect and Cidara Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Durect and Cidara Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Durect and Cidara Therapeutics, you can compare the effects of market volatilities on Durect and Cidara Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Durect with a short position of Cidara Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Durect and Cidara Therapeutics.

Diversification Opportunities for Durect and Cidara Therapeutics

-0.71

Correlation Coefficient

Durect  Cidara Therapeutics

Pay attention - limited upside

The 3 months correlation between Durect and Cidara is -0.71. Overlapping area represents the amount of risk that can be diversified away by holding Durect and Cidara Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cidara Therapeutics and Durect is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Durect are associated (or correlated) with Cidara Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cidara Therapeutics has no effect on the direction of Durect i.e., Durect and Cidara Therapeutics go up and down completely randomly.

Pair Corralation between Durect and Cidara Therapeutics

Given the investment horizon of 90 days Durect is expected to under-perform the Cidara Therapeutics. In addition to that, Durect is 1.16 times more volatile than Cidara Therapeutics. It trades about -0.14 of its total potential returns per unit of risk. Cidara Therapeutics is currently generating about 0.23 per unit of volatility. If you would invest  1,159  in Cidara Therapeutics on September 3, 2024 and sell it today you would earn a total of  862.00  from holding Cidara Therapeutics or generate 74.37% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Durect  vs.  Cidara Therapeutics

Durect

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Durect has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Cidara Therapeutics

Risk-Adjusted Performance

18 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Cidara Therapeutics are ranked lower than 18 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Cidara Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Durect and Cidara Therapeutics

The main advantage of trading using opposite Durect and Cidara Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Durect position performs unexpectedly, Cidara Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cidara Therapeutics will offset losses from the drop in Cidara Therapeutics' long position.

The idea behind Durect and Cidara Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.